Study title: Effect of CYP3A inhibition on vesnarinone metabolism in humans. Wandel C, Lang C C, Cowart D C, Girard A F, Bramer S, Flockhart D A, Wood A J. Clinical pharmacology and therapeutics, May 1998, vol. 63, no. 5, p. 506 11.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Bacterial Infections and Mycoses [C01] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: ERYTHROMYCIN | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |